Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

ABSTRACT: Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

PROVIDER: PRJNA788021 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17196900.fastq.gz	Fastqsanger.gz
	SRR17196901.fastq.gz	Fastqsanger.gz
	SRR17196902.fastq.gz	Fastqsanger.gz
	SRR17196903.fastq.gz	Fastqsanger.gz
	SRR17196904.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 57

Similar Datasets

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

Project description:Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

| PRJNA788030 | ENA

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

Project description:Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

| PRJNA788031 | ENA

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-09-18 | GSE190674 | GEO

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21189]

Project description:Using a mouse-adapted SARS-CoV-2 variant (SARS-CoV-2 MA20), newly generated in our lab, we found that endogenous type I and type III IFNs synergize to limit SARS-CoV-2 replication and to expedite virus clearance and that enhanced disease progression in aged mice depends on impaired type II IFN immunity

2022-09-19 | GSE190673 | GEO

Individual and combinatorial contribution of type I, II and III interferons in limiting SARS-CoV-2 replication, disease progression and age-related mortality [RN21061]

Project description:Using a mouse-adapted SARS-CoV-2 variant (SARS-CoV-2 MA), we found that endogenous type I and type III IFNs synergize to limit SARS-CoV-2 replication and to expedite virus clearance and that enhanced disease progression in aged mice depends on impaired type II IFN immunity

2022-09-19 | GSE190672 | GEO

Eutherian interferons

Project description:Eutherian interferons

| PRJEB36709 | ENA

ImmGen Cytokines: Interferons

Project description:ImmGen Cytokines: Interferons

| PRJNA303161 | ENA

Chicago Infant Mortality Study

Project description:Chicago Infant Mortality Study

| PRJNA1166343 | ENA

Chicago Infant Mortality Study

Project description:Chicago Infant Mortality Study

| PRJNA1166344 | ENA

Human lung tissue treated with interferons

Project description:RNAseq analysis of human lung slices after treatment with different interferons. Results: Differentially expressed genes were observed after treatment with different interferons. Methods: Tumor-free human lung explants were obtained from patients undergoing lung surgery at the University Hospital Muenster on the day of surgery. Tissue blocks were individually placed in a 12-well plate in RPMI medium. Tissues were treated with different interferons. RNA was prepared from tissue homogenates.

2022-08-31 | GSE188637 | GEO